...
首页> 外文期刊>Molecular vision >The effects of small interfering RNA–targeting tissue factor on an in vitro model of neovascularization
【24h】

The effects of small interfering RNA–targeting tissue factor on an in vitro model of neovascularization

机译:小干扰RNA靶向组织因子对新生血管形成体外模型的影响

获取原文

摘要

Purpose: Tissue factor (TF) plays an important role in neovascularization (NV). This study aimed to determine whether small interfering RNA–targeting TF (TF-siRNA) could knock down TF expression and inhibit cell proliferation, cell migration, and tube formation in an in vitro model of NV. Methods: Lipopolysaccharide (LPS) was used to stimulate human umbilical vein endothelial cell (HUVEC) lines to express TF and mimic certain phenotypes of NV in vitro. HUVECs were transfected with TF-siRNAs and control siRNAs using LipofectamineTM 2000. The inhibitory effect of the siRNAs on the expression of TF mRNA and protein was evaluated by quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) and western blot analysis. The effects on the cell viability, migration, and tube formation of siRNA-treated cells were examined by MTT assay, wound-healing assay, and Matrigel-induced capillary tube formation. Results: Lipopolysaccharide treatment increased the expression of TF. TF-siRNAs effectively knocked down TF expression, with the most efficient TF-siRNA reducing 78.9% of TF expression. TF protein was also notably curtailed by TF-siRNA. The MTT and wound-healing assays showed that the TF-siRNA substantially inhibited the proliferation and migration of HUVECs. Tube formation was decreased by 47.4% and 59.4% in cells treated with the TF-siRNA and vascular endothelial growth factor–siRNA, respectively, compared with the blank control. Conclusions: TF-siRNA can knockdown TF expression and inhibit cell proliferation, migration, and tube formation in vitro. TF-siRNA may provide a novel therapeutic candidate for NV-related diseases.
机译:目的:组织因子(TF)在新血管形成(NV)中起重要作用。这项研究旨在确定在NV体外模型中,靶向小分子干扰RNA的TF(TF-siRNA)是否可以抑制TF表达并抑制细胞增殖,细胞迁移和管形成。方法:脂多糖(LPS)用于体外刺激人脐静脉内皮细胞(HUVEC)表达TF并模拟NV的某些表型。使用LipofectamineTM 2000将HUVECs用TF-siRNA和对照siRNA转染。通过定量逆转录聚合酶链反应(RT-qPCR)和Western blot分析评估siRNA对TF mRNA和蛋白质表达的抑制作用。通过MTT测定,伤口愈合测定和Matrigel诱导的毛细管形成来检查对siRNA处理的细胞的细胞存活力,迁移和管形成的影响。结果:脂多糖处理可增加TF的表达。 TF-siRNA有效地降低了TF表达,而最有效的TF-siRNA降低了TF表达的78.9%。 TF-siRNA也明显减少了TF蛋白。 MTT和伤口愈合试验表明,TF-siRNA基本上抑制了HUVEC的增殖和迁移。与空白对照组相比,在用TF-siRNA和血管内皮生长因子–siRNA处理的细胞中,管形成分别减少了47.4%和59.4%。结论:TF-siRNA可以抑制TF的表达,并在体外抑制细胞的增殖,迁移和管形成。 TF-siRNA可能为NV相关疾病提供一种新型的治疗候选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号